Zentexia is a Danish R&D company specialized in developing new small molecules aimed at reversing aging at the cellular level.  

Zentexia develops novel therapeutic concepts for the life science industries through a proprietary interdisciplinary approach based on artificial intelligence (AI) and advanced systems biology.

AI is employed in all stages of development to provide pioneering efficacy, minimize development risk and optimize the probability of success. 

Zentexia’s novel active small molecules are aimed at a range of life science applications - pharmaceutical as well as adjacent regulatory categories like medical devices.

Zentexia's development programs are dedicated to asset maturation which enables several commercialization pathways with different risk profiles and value inflection points.